"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 8 | 2 | 10 |
| 2000 | 1 | 1 | 2 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 5 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 6 | 0 | 6 |
| 2005 | 4 | 0 | 4 |
| 2006 | 8 | 2 | 10 |
| 2007 | 6 | 2 | 8 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 0 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 9 | 4 | 13 |
| 2015 | 6 | 0 | 6 |
| 2016 | 2 | 7 | 9 |
| 2017 | 13 | 2 | 15 |
| 2018 | 13 | 4 | 17 |
| 2019 | 13 | 8 | 21 |
| 2020 | 19 | 7 | 26 |
| 2021 | 10 | 8 | 18 |
| 2022 | 6 | 25 | 31 |
| 2023 | 7 | 26 | 33 |
| 2024 | 30 | 10 | 40 |
| 2025 | 43 | 7 | 50 |
| 2026 | 14 | 0 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review. Blood Adv. 2026 May 26; 10(10):3467-3479.
-
Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. Blood. 2026 May 07; 147(19):2215-2225.
-
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr 23; 147(17):2011-2017.
-
LRRC15-CAR T Cells for the Treatment of Osteosarcoma. Clin Cancer Res. 2026 Apr 15; 32(8):1557-1573.
-
Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026 Mar 10; 10(5):1700-1712.
-
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Nat Biomed Eng. 2026 Apr; 10(4):803-814.
-
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium. Blood Adv. 2026 Feb 10; 10(3):725-732.
-
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor. Nat Commun. 2026 Feb 04; 17(1):1349.
-
Lung tumouroids as a testing platform for precision CAR T cell therapy. Nat Biomed Eng. 2026 Apr; 10(4):815-831.
-
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nat Med. 2026 Feb; 32(2):702-716.